EARNING RECAP

Align Technology Inc

#ALGN 2019 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q2 $1.83 est. $1.51 $600.70M est. $599.38M -26.99% ($200.90 closing price) $219.71 $197.11 52 weeks low; sees Q3 EPS $1.83 est. $1.51, revenue $585M-$600M est. $623.65M; sees Fy19 revenue at low end of 20%-30% target
Q1 89c est. 83c $548.97M est. $530.4M -.11% ($296.74 closing price0 $316 $286.61 record high; sees Q2 EPS $1.47- $1.54 est. $1.24, revenue $590M- $600M est. $592.75M;
#ALGN 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 $1.20 est. $1.15 $534M est. $512.7M +4.86% ($232.83 closing price) $234.44 $207.99 sees Q1 EPS 78c-84c est. $1.19; Q1 revenue 4525M- $535M est. $529.33M; sees Fy19 revenue growth in mid range of 20%- 30%, operating margin 15.1% -16.1%
Q3 $1.24 VS $1.19 $505.3M vs $502.65M -20.20% ($232.07 closing) $235.50 $203.12 Q4 EPS $1.10-$1.15, consensus $1.33
Q2 $1.30 est. $1.09 $490.3M est. $471.88M +1.79% ($91.15 closing) $91.50 $89.56 sees FY18 revenue growth in "low to mid 30s" sees Q3 EPS $1.13-$1.18 est. $1.19 Sees Q3 revenue $493M-$503M est. $500.4
Q1 $1.17 est. $98c $436.9M est. $408.25M +5.81% ($259.89 cloing) $266.10 $242.71 raises FY18 in the low 30%,previous view 15%-25%; sees Q2 revenue $40M-$470M est. $453.14M
#ALGN 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 13c may not compare to 9c $421.3M est. $396.17 -2.99% $270.60 $248.21 sees Q1 EPS 94c -98c est. 88c; revenue $400M-$410M est. $395.47M
Q3 $1.01 vs. 82c $383.3M vs. $359.82M +16.24% ($235.94 closing) $239.83 $223.56 Guides Q4 eps 92c-95c; revenue $391-$398M con. $368.08
Q2 $0.85 Vs $0.73 $356.5M Vs $344.00M +10.05% ($173.06 closing) $173.79 $160.37 Company said it now expects net revenue $of $355M to $360M in 3Q.
Q1 85c may not compare to 67c est $310.3M vs $297.39M +12.10% ($134.62 closing) $145.24 $133.71 +13.3% @ $136.00 AH. Q2 revenue $$340M-$345M, consensus $324.44M

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.